Effect of CCL3 on osteoblast in myeloma bone disease.
- Author:
Sijie ZHAO
1
;
Rong FU
1
;
Hui LIU
1
;
Yihao WANG
1
;
Lijuan LI
1
;
Chunyan LIU
1
;
Tian ZHANG
1
;
Shaoxue DING
1
;
Shan GAO
1
;
Erbao RUAN
1
;
Wen QU
1
;
Huaquan WANG
1
;
Xiaoming WANG
1
;
Yuhong WU
1
;
Jia SONG
1
;
Hong LIU
1
;
Jing GUAN
1
;
Zonghong SHAO
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Cells, Cultured; Chemokine CCL3; pharmacology; Female; Humans; Male; Middle Aged; Multiple Myeloma; pathology; Osteoblasts; cytology; drug effects; metabolism; Receptors, CCR1; metabolism; Young Adult
- From: Chinese Journal of Hematology 2014;35(7):623-627
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo culture osteoblast in vitro and evaluate CCL3 receptor CCR1 expression in patients with multiple myeloma (MM).
METHODSBone marrow osteoblasts from MM patients were cultured in vitro with dexamethasone, β-sodium glycerophosphate and vitamin C, which were identified by alkaline phosphatase staining, Von Kossa's staining. The CCL3 receptor expression was evaluated by flow cytometry. The morphology and quantity of osteoblast were observed after exposure to CCL3.
RESULTSBone marrow osteoblasts from MM patients could be cultured in vitro and be identified by positive staining of alkaline phosphatase and Von Kossa's. MM-derived osteoblasts expressed higher levels of CCR1 (74.48 ± 7.31)%, compared with normal controls (48.35 ± 8.81)%. Calcium deposition of osteoblasts after exposure to CCL3 was less than that of controls.
CONCLUSIONBone marrow osteoblasts could be cultured in vitro from MM Patients. CCL3 may contribute to the development of myeloma bone disease.
